Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer

被引:0
|
作者
Tao, Xiaoxuan [1 ]
Gao, Qichang [2 ]
Chen, Yiyang [1 ]
Cai, Nannan [1 ]
Hao, Chuncheng [1 ]
机构
[1] Harbin Med Univ, Canc Hosp, Dept Radiat Oncol, Harbin, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Harbin, Peoples R China
关键词
Stereotactic radiosurgery (SRT); Immunotherapy (IT); Targeted therapy (TT); Non-small cell lung cancer (NSCLC); Brain metastases (BM); RADIOSURGERY; THERAPY;
D O I
10.1007/s00066-024-02360-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveStereotactic radiotherapy (SRT) is fast gaining attention as a preferred treatment alternative for patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). In this study, we examined the efficacy and safety of combining SRT with immunotherapy (IT) and targeted therapy (TT), either separately or concurrently with the aim to formulate an optimal therapeutic regimen for patients with NSCLC BM.MethodsThe combination therapy were comprised of IT and TT agents. For the SRT-combined TT agents group, TT was limited to third-generation EGFR-TKIs. The administration of these drugs within 30 days before or after SRT was defined as combination therapy. The primary endpoint was 1-year progression-free survival (PFS), which was evaluated by a blinded independent review committee and categorized into local recurrence at the radiation site and the emergence of new distant intracranial metastases. Secondary endpoints included confirmed intracranial objective response rate (IORR) and intracranial disease control rate in the overall population. Post-treatment grading was performed according to CTCAE, and the levels of radiation necrosis were differentiated.ResultsThe 266 patients with NSCLC BM were categorized into the following four groups based on their treatment methods: SRT alone, SRT combined with IT, SRT combined with third-generation EGFR-TKIs, and SRT combined with both IT and TT. For the local radiation range, the 1-year PFS of these four groups were 77.89% (P = 0.239), 88.75% (P = 0.266), 88.01% (P = 0.210), and 91.97% (P = 0.057), respectively. For new intracranial metastases outside of the radiotherapy site, the corresponding values were 63.96% (P = 0.039), 74.17% (P = 0.258), 88.70% (P = 0.024), and 87.81% (P = 0.015), respectively. By the end of the study period, the IORR increased from 32% with SRT alone to 46% in the IT group, 58% in the TT group, and 61% in the SRT combined with both the IT and TT groups. However, the group that received SRT in combination with IT and TT exhibited a higher occurrence rate of grade 3 adverse events, and a statistically significant difference was observed in grade 3 radiation necrosis.ConclusionFor NSCLC BM, IT, TT, or both together with SRT increased the distant intracranial tumor control. Nonetheless, combining SRT with both IT and TT increased the occurrence rate of acute adverse events. Thus, while SRT provided good local control independently, the incidence of symptomatic RN was low.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations
    Hao, Yue
    Xu, Manyi
    Jin, Jianan
    Si, Jinfei
    Xu, Chunwei
    Song, Zhengbo
    CANCER MEDICINE, 2023, 12 (15): : 15903 - 15911
  • [42] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Mari Tone
    Kota Iwahori
    Takayuki Shiroyama
    Shinji Futami
    Yujiro Naito
    Kiyoharu Fukushima
    Kotaro Miyake
    Shohei Koyama
    Haruhiko Hirata
    Izumi Nagatomo
    Hisashi Wada
    Yoshito Takeda
    Atsushi Kumanogoh
    Scientific Reports, 13
  • [43] Efficacy and safety analysis of stereotactic body radiotherapy for brain multi-metastases in non-small cell lung cancer patients
    Zhao, Jie
    Liu, Haiming
    Qi, Tao
    Zhao, Hui
    Ye, Tingting
    Ning, Peng
    TECHNOLOGY AND HEALTH CARE, 2024, 32 (01) : 293 - 301
  • [44] A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer
    Cui, Ran
    Wei, Chun
    Li, Xianyi
    Jiang, Ou
    MEDICINE, 2022, 101 (47) : E31894
  • [45] Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastases
    Luo, S.
    Meng, L.
    Li, P.
    Gong, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S621 - S621
  • [46] Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy
    Sanoyan, D. Akhoundova
    Hullner, M.
    Kraft, J.
    Bankel, L.
    Lee, S.
    Ansratschke, N.
    Fontecedro, A. Curioni
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S930 - S930
  • [47] Metformin Enhances the Efficacy of EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Patients With Type 2 Diabetes Mellitus
    Han, R.
    Jia, Y.
    Li, X.
    Zhao, C.
    Zhao, S.
    Liu, S.
    Liu, Y.
    Qiao, M.
    Li, J.
    Gao, G.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S588 - S588
  • [48] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Tone, Mari
    Iwahori, Kota
    Shiroyama, Takayuki
    Futami, Shinji
    Naito, Yujiro
    Fukushima, Kiyoharu
    Miyake, Kotaro
    Koyama, Shohei
    Hirata, Haruhiko
    Nagatomo, Izumi
    Wada, Hisashi
    Takeda, Yoshito
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [49] Outcomes of EGFR-TKIs for patients with non-small cell lung cancer harboring EGFR mutations with poor performance status
    Hashimoto, K.
    Okuma, Y.
    Hakozaki, T.
    Watanabe, K.
    Hosomi, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer
    Cheng, Zhinan
    Cui, Hongwei
    Wang, Yaqi
    Yang, Jin
    Lin, Chunyang
    Shi, Xiaoyu
    Zou, Yuxiu
    Chen, Jing
    Jia, Xiaoqiong
    Su, Liqing
    ONCOLOGY REPORTS, 2024, 51 (01)